{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:00:33Z","timestamp":1790596833364,"version":"4.1.0"},"reference-count":82,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Vancomycin-associated acute kidney injury (AKI) is a popular topic in the medical literature with few clear answers. While many studies evaluate the risk of AKI associated with vancomycin, few data are high quality and\/or long in duration of follow-up. This review takes the clinician through an approach to evaluate a patient for risk of AKI. This evaluation should include patient assessment, antibiotic prescription, duration, and monitoring. Patient assessment involves evaluating severity of illness, baseline renal function, hypotension\/vasopressor use, and concomitant nephrotoxins. Evaluation of antibiotic prescription includes evaluating the need for methicillin-resistant Staphylococcus aureus (MRSA) coverage and\/or vancomycin use. Duration of therapy has been shown to increase the risk of AKI. Efforts to de-escalate vancomycin from the antimicrobial regimen, including MRSA nasal swabs and rapid diagnostics, should be used to lessen the likelihood of AKI. Adequate monitoring includes therapeutic drug monitoring, ongoing fluid status evaluations, and a continual reassessment of AKI risk. The issues with serum creatinine make the timely evaluation of renal function and diagnosis of the cause of AKI problematic. Most notably, concomitant piperacillin-tazobactam can increase serum creatinine via tubular secretion, resulting in higher rates of AKI being reported. The few studies evaluating the long-term prognosis of AKI in patients receiving vancomycin have found that few patients require renal replacement therapy and that the long-term risk of death is unaffected for patients surviving after the initial 28-day period.<\/jats:p>","DOI":"10.3390\/jcm8060781","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T02:08:40Z","timestamp":1559527720000},"page":"781","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Utilizing the Patient Care Process to Minimize the Risk of Vancomycin-Associated Nephrotoxicity"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8528-7589","authenticated-orcid":false,"given":"Ashley R.","family":"Selby","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy, Dallas, TX 75235, USA"},{"name":"VA North Texas Health Care System, Dallas, TX 75216, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5616-8246","authenticated-orcid":false,"suffix":"II","given":"Ronald G.","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy, Dallas, TX 75235, USA"},{"name":"VA North Texas Health Care System, Dallas, TX 75216, USA"},{"name":"Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"},{"name":"Dose Optimization and Outcomes Research (DOOR) Program, Dallas, TX 75235, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.amjmed.2009.05.031","article-title":"Vancomycin-associated nephrotoxicity: Grave concern or death by character assassination?","volume":"123","author":"Hazlewood","year":"2010","journal-title":"Am. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1128\/AAC.23.1.138","article-title":"Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981","volume":"23","author":"Farber","year":"1983","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1001\/archinte.1989.00390080053013","article-title":"Mild nephrotoxicity associated with vancomycin use","volume":"149","author":"Downs","year":"1989","journal-title":"Arch. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: A summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/jamainternmed.2016.5651","article-title":"Estimating national trends in inpatient antibiotic use among us hospitals from 2006 to 2012","volume":"176","author":"Baggs","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","article-title":"A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia","volume":"29","author":"Jeffres","year":"2007","journal-title":"Clin. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/TA.0b013e3182a74b70","article-title":"Vancomycin and nephrotoxicity; just another myth?","volume":"75","author":"Davies","year":"2013","journal-title":"J. Trauma Acute Care Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2050-6511-14-12","article-title":"Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: A retrospective cohort study","volume":"14","author":"Hall","year":"2013","journal-title":"BMC Pharmacol. Toxicol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.amjmed.2010.07.025","article-title":"Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity","volume":"123","author":"Pritchard","year":"2010","journal-title":"Am. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/17512433.2018.1471984","article-title":"Impact of total body weight on acute kidney injury in patients with gram-negative bacteremia","volume":"11","author":"Hall","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijantimicag.2018.11.002","article-title":"Impact of piperacillin\/tazobactam on nephrotoxicity in patients with Gram-negative bacteraemia","volume":"53","author":"Hall","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.12788\/jhm.2684","article-title":"Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: A retrospective cohort analysis","volume":"12","author":"Rutter","year":"2017","journal-title":"J. Hosp. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1128\/AAC.00173-11","article-title":"Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients","volume":"55","author":"Minejima","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/1060028018757497","article-title":"Comparison of the nephrotoxicity of vancomycin in combination with cefepime, meropenem, or piperacillin\/tazobactam: A prospective, multicenter study","volume":"52","author":"Mullins","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.1128\/AAC.00168-11","article-title":"Relationship between vancomycin trough concentrations and nephrotoxicity: A prospective multicenter trial","volume":"55","author":"Bosso","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1345\/aph.1R158","article-title":"The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran\u2019s population: A retrospective analysis","volume":"46","author":"Horey","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/phar.1423","article-title":"Vancomycin-associated nephrotoxicity in adult medicine patients: Incidence, outcomes, and risk factors","volume":"34","author":"Meaney","year":"2014","journal-title":"Pharmacotherapy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"Paterson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","article-title":"Aminoglycosides: Nephrotoxicity","volume":"43","author":"Tulkens","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1179\/joc.2000.12.6.463","article-title":"Amphotericin B-induced nephrotoxicity: A review","volume":"12","author":"Fanos","year":"2000","journal-title":"J. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1177\/0310057X1504300507","article-title":"Factors associated with vancomycin nephrotoxicity in the critically ill","volume":"43","author":"Hanrahan","year":"2015","journal-title":"Anaesth. Intensive Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e02089-16","DOI":"10.1128\/AAC.02089-16","article-title":"Nephrotoxicity during vancomycin therapy in combination with piperacillin-tazobactam or cefepime","volume":"62","author":"Rutter","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","first-page":"666","article-title":"Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin\/tazobactam","volume":"64","author":"Hammond","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/CCM.0000000000002769","article-title":"Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: A systematic review and meta-analysis","volume":"46","author":"Luther","year":"2018","journal-title":"Crit. Care Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.ijantimicag.2018.08.001","article-title":"Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin\/tazobactam in combination or as monotherapy","volume":"52","author":"Carreno","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/phar.1738","article-title":"Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam or cefepime: A retrospective cohort study","volume":"36","author":"Hammond","year":"2016","journal-title":"Pharmacotherapy"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcrc.2018.08.007","article-title":"Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin\/tazobactam or cefepime in the intensive care unit","volume":"48","author":"Buckley","year":"2018","journal-title":"J. Crit. Care"},{"key":"ref_31","unstructured":"Schreier, D.J., Kashani, K.B., Sakhuja, A., Mara, K.C., Toottooni, M.S., Personett, M.S., Nelson, S., Rule, A.D., Steckelberg, J.M., and Tande, A.J. (2018). Incidence of acute kidney injury among critically ill patients with brief empiric use of antipseudomonal \u03b2-lactams with vancomycin. Clin. Infect. Dis., Epub ahead of print."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/phar.1918","article-title":"Acute kidney injury in patients treated with iv beta-lactam\/beta-lactamase inhibitor combinations","volume":"37","author":"Rutter","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/ncpneph0076","article-title":"Drug-associated renal dysfunction and injury","volume":"2","author":"Choudhury","year":"2006","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Pais, G.M., Liu, J., Avedissian, S.N., Xanthos, T., Chalkias, A., d\u2019Aloja, E., Locci, E., Gilchrist, A., Prozialeck, W.C., and Rhodes, N.J. (2019). Urinary Biomarker and Histopathological Evaluation of Vancomycin and Piperacillin Tazobactam Nephrotoxicity in Comparison with Vancomycin in a Rat Model and a Confirmatory Cellular Model. bioRxiv, Epub ahead of print.","DOI":"10.1101\/568907"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2","DOI":"10.7547\/1030002","article-title":"2012 infectious diseases society of america clinical practice guideline for the diagnosis and treatment of diabetic foot infections","volume":"103","author":"Lipsky","year":"2013","journal-title":"J. Am. Podiatr. Med. Assoc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1086\/425368","article-title":"Practice guidelines for the management of bacterial meningitis","volume":"39","author":"Tunkel","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/sur.2013.9999","article-title":"Clinical practice guidelines for antimicrobial prophylaxis in surgery","volume":"14","author":"Bratzler","year":"2013","journal-title":"Surg. Infect. (Larchmt)"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.chest.2018.10.014","article-title":"Outcomes associated with de-escalating therapy for methicillin-resistant Staphylococcus aureus in culture-negative nosocomial pneumonia","volume":"155","author":"Cowley","year":"2019","journal-title":"Chest"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/AAC.01805-13","article-title":"Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia","volume":"58","author":"Dangerfield","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciy024","article-title":"The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: A diagnostic meta-analysis with antimicrobial stewardship implications","volume":"67","author":"Parente","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e02432-16","DOI":"10.1128\/AAC.02432-16","article-title":"Nasal methicillin-resistant Staphylococcus aureus (MRSA) PCR testing reduces the duration of MRSA-targeted therapy in patients with suspected MRSA pneumonia","volume":"61","author":"Baby","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0009-9236(96)90060-0","article-title":"Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies","volume":"60","author":"Calvo","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1681\/ASN.2016080867","article-title":"Vancomycin-Associated Cast Nephropathy","volume":"28","author":"Luque","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/1469-0691.12695","article-title":"Impact of source of infection and vancomycin AUC0-24\/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"20","author":"Ghosh","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e02042-17","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Aljefri, D.M., Avedissian, S.N., Rhodes, N.J., Postelnick, M.J., Nguyen, K., and Scheetz, M.H. (2019). Vancomycin Area under the Curve and Acute Kidney Injury: A Meta-analysis. Clin. Infect. Dis., Epub ahead of print.","DOI":"10.1093\/cid\/ciz051"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00134-017-4832-y","article-title":"Prevention of acute kidney injury and protection of renal function in the intensive care unit: Update 2017: Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine","volume":"43","author":"Joannidis","year":"2017","journal-title":"Intensive Care Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/s13054-015-1163-7","article-title":"Fluid overload and acute kidney injury: Cause or consequence?","volume":"19","author":"Ostermann","year":"2015","journal-title":"Crit. Care"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00075198-200212000-00005","article-title":"Developing a consensus classification system for acute renal failure","volume":"8","author":"Kellum","year":"2002","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure\u2014Definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit. Care"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network. cute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit. Care"},{"key":"ref_62","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO), and Acute Kidney Injury Work Group (2012). KDIGO clinical practice guidelines for acute kidney injury. Kidney Int. Suppl., 2."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/clinchem\/38.10.1933","article-title":"Serum creatinine as an index of renal function: New insights into old concepts","volume":"38","author":"Perrone","year":"1992","journal-title":"Clin. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/000456328602300101","article-title":"Analytical reviews in clinical biochemistry: The estimation of creatinine","volume":"23","author":"Spencer","year":"1986","journal-title":"Ann. Clin. Biochem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/ajcn\/37.3.478","article-title":"Measurement of muscle mass in humans: Validity of the 24-hour urinary creatinine method","volume":"37","author":"Heymsfield","year":"1983","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1681\/ASN.2008070669","article-title":"Creatinine kinetics and the definition of acute kidney injury","volume":"20","author":"Waikar","year":"2009","journal-title":"Am. Soc. Nephrol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000328911","article-title":"Trimethoprim, creatinine and creatinine-based equations","volume":"119","author":"Delanaye","year":"2011","journal-title":"Nephron Clin. Pract."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/0140-6736(92)92502-7","article-title":"Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate","volume":"340","author":"Koomen","year":"1992","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1128\/AAC.37.5.1056","article-title":"Pyrimethamine inhibits renal secretion of creatinine","volume":"37","author":"Opravil","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/QAI.0b013e3182645648","article-title":"Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function","volume":"61","author":"German","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_71","first-page":"144","article-title":"Novel antiretroviral drugs and renal function monitoring of HIV patients","volume":"16","author":"Maggi","year":"2014","journal-title":"AIDS Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nbt0510-436","article-title":"Next-generation biomarkers for detecting kidney toxicity","volume":"28","author":"Bonventre","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e00416-17","DOI":"10.1128\/AAC.00416-17","article-title":"24-Hour pharmacokinetic relationships for vancomycin and novel urinary biomarkers of acute kidney injury","volume":"61","author":"Rhodes","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Pais, G.M., Avedissian, S.N., O\u2019Donnell, J.N., Rhodes, N.J., Lodise, T.P., Prozialeck, W.C., Lamar, P.C., Cluff, C., Gulati, A., and Fitzgerald, J.C. (2019). Comparative performance of urinary biomarkers for vancomycin induced kidney injury according to timeline of injury. Antimicrob. Agents Chemother., Epub ahead of print.","DOI":"10.1128\/AAC.00079-19"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Dorshow, R.B., Asmelash, B., Chinen, L.K., Debreczeny, M.P., Fitch, R.M., Freskos, J.K., Galen, K.P., Gaston, K.R., Marzan, T.A., and Poreddy, A.R. (2008). New Optical Probes for the Continuous Monitoring of Renal Function, SPIE. Proceedings of SPIE.","DOI":"10.1117\/12.763697"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.294.7.813","article-title":"Acute renal failure in critically ill patients: A multinational, multicenter study","volume":"294","author":"Uchino","year":"2005","journal-title":"JAMA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1681\/ASN.2005060668","article-title":"Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001","volume":"17","author":"Xue","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1164\/rccm.201311-2097OC","article-title":"Small acute increases in serum creatinine are associated with decreased long-term survival in the critically ill","volume":"189","author":"Linder","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.medmal.2013.09.011","article-title":"The ZEPHyR study: A randomized comparison of linezolid and vancomycin for MRSA pneumonia","volume":"43","author":"Chavanet","year":"2013","journal-title":"Med. Mal. Infect."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: A systematic review","volume":"21","author":"Payne","year":"2017","journal-title":"Crit. Care"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1060028016673858","article-title":"Randomized controlled trial to determine the efficacy of early switch from vancomycin to vancomycin alternatives as a strategy to prevent nephrotoxicity in patients with multiple risk factors for adverse renal outcomes (STOP-NT)","volume":"51","author":"Carreno","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00134-016-4670-3","article-title":"Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: The PrevAKI randomized controlled trial","volume":"43","author":"Meersch","year":"2017","journal-title":"Intensive Care Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/6\/781\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:55:28Z","timestamp":1760187328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/6\/781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":82,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["jcm8060781"],"URL":"https:\/\/doi.org\/10.3390\/jcm8060781","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}